These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27130427)

  • 1. APASL consensus statements and recommendation on treatment of hepatitis C.
    Omata M; Kanda T; Wei L; Yu ML; Chuang WL; Ibrahim A; Lesmana CR; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Dokmeci AK; Mamun-Al-Mahtab ; McCaughan GW; Wasim J; Crawford DH; Kao JH; Yokosuka O; Lau GK; Sarin SK
    Hepatol Int; 2016 Sep; 10(5):702-26. PubMed ID: 27130427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.
    Omata M; Kanda T; Wei L; Yu ML; Chuang WL; Ibrahim A; Lesmana CR; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Dokmeci AK; Al-Mahtab M; McCaughan GW; Wasim J; Crawford DH; Kao JH; Yokosuka O; Lau GK; Sarin SK
    Hepatol Int; 2016 Sep; 10(5):681-701. PubMed ID: 27229718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APASL consensus statements and management algorithms for hepatitis C virus infection.
    Omata M; Kanda T; Yu ML; Yokosuka O; Lim SG; Jafri W; Tateishi R; Hamid SS; Chuang WL; Chutaputti A; Wei L; Sollano J; Sarin SK; Kao JH; McCaughan GW
    Hepatol Int; 2012 Apr; 6(2):409-35. PubMed ID: 26201405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
    Omata M; Lesmana LA; Tateishi R; Chen PJ; Lin SM; Yoshida H; Kudo M; Lee JM; Choi BI; Poon RT; Shiina S; Cheng AL; Jia JD; Obi S; Han KH; Jafri W; Chow P; Lim SG; Chawla YK; Budihusodo U; Gani RA; Lesmana CR; Putranto TA; Liaw YF; Sarin SK
    Hepatol Int; 2010 Mar; 4(2):439-74. PubMed ID: 20827404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C in Asia: when East meets West.
    Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
    Chevaliez S; Asselah T
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S31-41. PubMed ID: 21742299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon.
    Kim SK; Kim SR; Imoto S; Tohyama M; Otono Y; Tamura T; Kim KI; Kobayashi M; Ohtani A; Sugimoto K; Mizuguchi A; Hiramatsu Y; Kudo M
    Oncology; 2015; 89 Suppl 2():60-9. PubMed ID: 26584037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).
    Sarin SK; Kumar A; Almeida JA; Chawla YK; Fan ST; Garg H; de Silva HJ; Hamid SS; Jalan R; Komolmit P; Lau GK; Liu Q; Madan K; Mohamed R; Ning Q; Rahman S; Rastogi A; Riordan SM; Sakhuja P; Samuel D; Shah S; Sharma BC; Sharma P; Takikawa Y; Thapa BR; Wai CT; Yuen MF
    Hepatol Int; 2009 Mar; 3(1):269-82. PubMed ID: 19669378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel.
    Viganò M; Perno CF; Craxì A;
    Dig Liver Dis; 2017 Jul; 49(7):731-741. PubMed ID: 28456519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.
    Bradshaw D; Mbisa JL; Geretti AM; Healy BJ; Cooke GS; Foster GR; Thomson EC; McLauchlan J; Agarwal K; Sabin C; Mutimer D; Moss P; Irving WL; Barnes E;
    J Infect; 2019 Dec; 79(6):503-512. PubMed ID: 31629015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy.
    El-Khazragy N; Elshimy AA; Hassan SS; Shaaban MH; Bayoumi AH; El Magdoub HM; Ghozy S; Gaballah A; Aboelhussein MM; Abou Gabal HH; Bannunah AM; Mansy AE
    Mol Carcinog; 2020 Dec; 59(12):1382-1391. PubMed ID: 33074585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to the treatment-naïve patient with HCV genotype 1 infection.
    Muir AJ
    Infect Dis Clin North Am; 2012 Dec; 26(4):893-901. PubMed ID: 23083822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 15. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.
    Liaw YF; Leung N; Guan R; Lau GK; Merican I; McCaughan G; Gane E; Kao JH; Omata M;
    Liver Int; 2005 Jun; 25(3):472-89. PubMed ID: 15910483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New combination attains a response rate of 90].
    Warpakowski A
    MMW Fortschr Med; 2015 Sep; 157(15):71. PubMed ID: 26349741
    [No Abstract]   [Full Text] [Related]  

  • 19. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents.
    Olsen DB; Davies ME; Handt L; Koeplinger K; Zhang NR; Ludmerer SW; Graham D; Liverton N; MacCoss M; Hazuda D; Carroll SS
    Antimicrob Agents Chemother; 2011 Feb; 55(2):937-9. PubMed ID: 21115793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.